While the Democratic Republic of the Congo (DRC), the epicentre of mpox, has yet to get a single vaccine dose despite battling large outbreaks since 2022, a flurry of activity last week aims to finally change this.

Last Friday, UNICEF announced it had issued an emergency tender for the procurement of mpox vaccines.

Usually, the World Health Organization (WHO) has to issue an emergency use listing (EUL) or full approval before UNICEF or the vaccine alliance, Gavi, can procure vaccines.

But WHO Director-General Dr Tedros Adhanom Ghebreyesus clarified at a media briefing last Friday that the global body has given UNICEF and Gavi authorisation to waive the usual procedure to speed up the procurement of the vaccines.

The emergency tender allows UNICEF to set up conditional supply agreements with vaccine manufacturers that will enable it “to purchase and ship vaccines without delay once countries and partners have secured financing, confirmed demand and readiness, and the regulatory requirements for accepting the vaccines are in place”, said UNICEF.  

UNICEF is also coordinating vaccine donations with the vaccine platform, Gavi, the Africa Centre for Disease Control and Prevention (Africa CDC), WHO and Pan American Health Organization (PAHO).

Derrick Sim, Gavi’s interim chief vaccine programmes officer, said that the tender enables “UNICEF to purchase and deliver vaccines after Gavi and other partners make funding available and sign purchase or donation agreements with manufacturers for the most immediate dose needs”.

“Securing access to supply and financing, delivering doses, and in parallel ensuring countries are ready to administer them, are all vital actions that need to be conducted rapidly but thoroughly, and in a coordinated manner. We welcome this tender as another positive step our alliance and Africa CDC are taking in this response,” added Sims.

Meanwhile, Africa CDC Director General Dr Jean Kaseya said he expects the DRC to start receiving donated vaccines from the US and EU this week.

No approval for mpox vaccines

The WHO decision on EULs for the two vaccines – Bavarian Nordic’s Jynneous (also called MVA-BN) and the Japanese company KM Biologics’ LC16 – is expected in mid-September. As they are already authorised in the European Union and USA, this is expected to be straight forward. 

The DRC issued emergency use approval for the vaccines in late June, but some other African countries with mpox outbreaks – including Burundi, Rwanda, Uganda and Kenya –  have yet to do so.

This will make their access more difficult and once again underscores how useful and important the African Medicines Agency (AMA), currently in the process of being set up, will be in health emergencies. 

Over 18,000 suspected mpox cases, including 629 deaths, have been reported in the DRC so far this year. Four out of five deaths have been in children.

‘Scramble for funds’

The WHO estimates that $135 million is needed to address mpox. Currently, each mpox vaccine costs $100.

Helen Clark, former co-chair of the Independent Panel for Pandemic Preparedness and Response, called on Gavi and other donors to see whether they can use some $1.8 billion left in the COVID-19 vaccine platform, COVAX, for vaccine access for the mpox response. 

“This current scramble for funds is a major reason why The Independent Panel recommended the establishment of an emergency surge finance mechanism – a recommendation which is highly relevant right now,” said Clark in a statement issued on behalf of all active members of the Independent Panel.

“The most urgent focus and investment on the ground must be on rolling out and intensifying basic public health measures,” added Clark.

Focus on public health measures

“It is clear that existing diagnostics cannot be immediately scaled, the vaccines available are insufficient in number and will take time to deploy, and there currently is no proven treatment. 

The spread and harm of mpox can and must be reduced by public health measures that are tailored to the affected communities and to the transmission patterns of the local outbreak. This includes support to health facilities and health workers, and investment in community risk communication and engagement to ensure people understand the risks of both zoonotic infection and human-to-human transmission.”

Over the weekend, over 75 organisations under the Pandemic Action Network sent a letter to the G20 Health Working Group meeting currently underway, urging them to prioritise “the immediate need for resources, including vaccines, to address the mpox outbreak”. 

“The G20 must honour its commitment to prioritising prevention, preparedness, and response to pandemics, including boosting local and regional production of medicines, vaccines, and strategic health supplies,” the letter added.

Image Credits: Eugene Kabambi/ WHO, Guerchom Ndebo/ WHO.